Biofourmis has spent years trying to figure out how to help care for patients with heart failure, cancer, and other debilitating diseases with the help of technology. Now, as it looks to scale, it must prove that it can deliver on its promises to improve care and cut costs.
The Boston-based company just got a vote of confidence from investors and large health care players with a $300 million Series D round, led by General Atlantic with participation from CVS Health and others. The funding, which values the Boston-based company at nearly $1.3 billion, underscores growing optimism about the potential of technology to take some kinds of health care out of hospitals and into patients’ homes.